Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats  by De Jong, Wim H. et al.
lable at ScienceDirect
Biomaterials 34 (2013) 8333e8343Contents lists avaiBiomaterials
journal homepage: www.elsevier .com/locate/biomater ia lsSystemic and immunotoxicity of silver nanoparticles in an intravenous
28 days repeated dose toxicity study in rats
Wim H. De Jong*, Leo T.M. Van Der Ven, Annemarie Sleijffers, Margriet V.D.Z. Park,
Eugene H.J.M. Jansen, Henk Van Loveren, Rob J. Vandebriel
Centre for Health Protection, National Institute for Public Health and The Environment (Rijksinstituut voor Volksgezondheid en Milieu, RIVM), PO Box 1,
3720 BA Bilthoven, The Netherlandsa r t i c l e i n f o
Article history:
Received 18 June 2013
Accepted 23 June 2013
Available online 22 July 2013
Keywords:
Nanosilver
Nanotoxicity
Intravenous
28 Days repeated dose study* Corresponding author.
E-mail address: wim.de.jong@rivm.nl (W.H. De Jon
0142-9612 2013 The Authors. Published by Elsevier
http://dx.doi.org/10.1016/j.biomaterials.2013.06.048a b s t r a c t
Because of its antibacterial activity nanosilver is one of the most commonly used nanomaterials. It is
increasingly used in a variety of both medical and consumer products resulting in an increase in human
exposure. However, the knowledge on the systemic toxicity of nanosilver is relatively limited. To
determine the potential systemic toxicity of silver nanoparticles (Ag-NP) with different sizes (20 nm and
100 nm) a 28-days repeated dose toxicity study was performed in rats using intravenous administration.
The toxic effect of the 20 nm Ag-NP was performed using the bench mark dose (BMD) approach.
Treatment with a maximum dose of 6 mg/kg body weight was well tolerated by the animals. However,
both for 20 nm and 100 nm Ag-NP growth retardation was observed during the treatment. A severe
increase in spleen size and weight was present which was due to an increased cell number. Both T and B
cell populations showed an increase in absolute cell number, whereas the relative cell numbers remained
constant. At histopathological evaluation brown and black pigment indicating Ag-NP accumulation was
noted in spleen, liver, and lymph nodes. Ag-NP was also detected incidentally in other organs. Clinical
chemistry indicated liver damage (increased alkaline phosphatase, alanine transaminase, and aspartate
transaminase) that could not be conﬁrmed by histopathology. Hematology showed a decrease in several
red blood cell parameters.
The most striking toxic effect was the almost complete suppression of the natural killer (NK) cell
activity in the spleen at high doses. Other immune parameters affected were: decreased interferon-g and
interleukin (IL)-10 production by concanavalin-A stimulated spleen cells, increased IL-1b and decreased
IL-6, IL-10 and TNF-a production by lipopolysaccharide stimulated spleen cells, increase in serum IgM
and IgE, and increase in blood neutrophilic granulocytes. For the spleen weight a critical effect dose of
0.37 mg/kg body weight (b.w.) could be established. The lowest critical effect dose (CED) for a 5% change
compared to control animals was observed for thymus weight (CED05 0.01 mg/kg b.w.) and for func-
tional immune parameters, i.e. decrease in NK cell activity (CED05 0.06 mg/kg b.w.) and LPS stimulation
of spleen cells (CED05 0.04 mg/kg b.w.). These results show that for nanosilver the most sensitive pa-
rameters for potential adverse responses were effects on the immune system.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Silver nanoparticles (Ag-NP) are frequently used in consumer
and medical products because of their antimicrobial activity [1e7].
Despite the rapidly growing presence of silver-containingg).
Ltd. Open access under CC BY-NC-ND licennanoproducts on the market [5e8], there is only limited informa-
tion on the possible risks of exposure to silver nanoparticles. In
recent reviews evaluating the risk assessment of silver nano-
particles, different knowledge gaps were identiﬁed, including tox-
icokinetics [4,9,10]. Similar data gaps were identiﬁed for the
possible registration of nanosilver as a substance under the EU
REACH regulation [11]. Previously we identiﬁed the spleen and liver
as main target organs for various nanomaterials after intravenous
administration [12e14]. This can be explained by the fact that these
organs are part of the reticulo-endothelial system (RES) that has
removing foreign agents from the circulation as one of its functions.
In vitro studies demonstrated that Ag-NP are cytotoxic by theirse. 
Table 1
Characteristics of BioPure silver nanoparticles.a
Parameter 20 nm CTH1359 100 nmCTH1409
Size  SD (nm) 21.0  2.6 107  7.6
Coefﬁcient of variation (%) 12.2 7.1
Size range (minemax diameter) 12.4e27.9 92.8e128.4
Number of particles (ml1) 3.9  1013 3.8  1011
Surface area per particle (nm2) 1.40  103 3.62  104
Surface area (nm2/ml) 5.49  1016 1.37  1016
Silver concentration (mg/ml) 2 2.6
Zeta potential (mV) 40.8 38.7
a Information provided by manufacturer nanoComposix, San Diego, USA.
Table 2
Dose levels and experimental design of 28 days repeated dose toxicity study with
Ag-NP.
Treatment Dose (mg/kg b.w. per day) n (MeF)
Phosphate buffer 0 2e2
Phosphate buffer 0 2e2
20 nm nanosilver 0.0082 2e2
20 nm nanosilver 0.0025 2e2
20 nm nanosilver 0.074 2e2
20 nm nanosilver 0.22 3e3
20 nm nanosilver 0.67 3e3
20 nm nanosilver 2 3e3
20 nm nanosilver 6 3e3
Phosphate buffer 0 2e2
100 nm nanosilver 6 4e4
W.H. De Jong et al. / Biomaterials 34 (2013) 8333e83438334effect on cellular metabolism and membrane integrity, and inhibit
embryonic stem cell differentiation [15].
In repeated dose toxicity inhalation studies animals were
exposed for 28 and 90 days in a whole body exposure chamber
using a nanoparticle generator for the production of silver nano-
particles [16e18]. In the ﬁrst evaluation of the 28-days toxicity
study with 12e15 nm Ag-NP general toxicity parameters, i.e. body
weight, hematology and blood clinical chemistry values, did not
indicate systemic toxicity at the doses investigated [16]. At histo-
pathological examination only incidentally some liver alterations
(cytoplasmic vacuolisation or hepatic necrosis) were observed. In-
dications for local reactions in the lung were absent [16]. The tissue
concentration of silver as determined with atomic absorption
spectrometry showed a dose dependent increase in the lung and
low concentrations in liver and brain. In the 90-days repeated dose
inhalation toxicity study lung function was impaired, and in-
dications for lung inﬂammation were noted by cellular and protein
content of the bronchoalveolar lavage ﬂuid (BALF) and lung histo-
pathology [17]. In a 28-days oral toxicity study with 60 nm silver
nanoparticles by Kim et al. [19], a dose dependent increase in silver
content was observed in all tissues investigated (testis, kidneys,
liver, brain, lung, stomach, blood). There was no effect on body
weight although some blood biochemistry parameters (alkaline
phosphatase, cholesterol) indicated some liver damage [19]. In a
recent 28-days oral toxicity study Van Der Zande et al. [20] found
that the silver concentration in organs was highly correlated with
the Agþ ion content of the nanosilver suspension. The highest
concentrations were observed in liver and spleen [20]. In general
the studies using either inhalation or oral exposure did not show
severe systemic toxicity, probably because of the relatively low
systemic exposure to nanosilver that is due to low absorption of the
nanosilver from the lung and gastrointestinal tract (GI-tract).
To avoid limited systemic exposure due to the cellular barriers
present in lung and GI-tract, we used intravenous administration of
nanosilver to evaluate its potential systemic toxicity. We investi-
gated the in vivo toxicity of two sizes of Ag-NP (20 nm and 100 nm)
in a repeated dose toxicity study after intravenous administration
for 28 days. Special emphasis was on the effects of the spleen as
part of the immune system as our previous results showed accu-
mulation of Ag-NP in the spleen [13].
2. Materials and methods
2.1. Animals
Male and female Wistar derived WU rats, 8 weeks of age, obtained from Harlan
Nederland BV, Horst, The Netherlands, were used. Animals were bred under SPF
conditions and barrier maintained during the experiment. Drinking water and
conventional feed were provided ad libitum. Husbandry conditions were maintained
according to all applicable provisions of the national laws, Experiments on Animals
Decree and Experiments on Animals Act. The experiment was approved by an in-
dependent ethical committee prior to the study according to the Dutch legislation.
2.2. Chemicals
BioPure silver nanoparticles, 20 nm diameter and 100 nm diameter in 2 mM
phosphate buffer were obtained from NanoComposix, San Diego, CA, USA. The
nanosilver dispersions provided were characterized with minimal agglomeration or
aggregation. The nanoparticle characteristics are presented in Table 1.
2.3. Experimental design
The present study was performed according to the general principles of OECD
guideline 407 (“Repeated dose 28-day oral study in rodents”) with some adjust-
ments. The animals were exposed to nanosilver particles via intravenous adminis-
tration. Instead of the usual design of three dose groups (low,mid and high dose) and
one control group, we increased the number of dose groups, at the expense of the
group sizes, i.e. while keeping the total number of animals the same.With this design,
and by applying the bench mark dose (BMD) approach [21], an improved charac-
terization of the dose response is obtainedwithout increasing the number of animals.Because of the known accumulation in the spleen [13] additional tests with spleen
cells were performed for possible immunotoxicological properties of nanosilver. In
addition not all organs indicated in OECD 407 were evaluated by histopathology.
Animals were divided in 11 groups and were intravenously injected (tail vein)
once a day for 28 days to either 1 ml nanosilver dispersion or vehicle control
(phosphate buffer). Dose levels and experimental design are presented in Table 2.
The experiment was performed in two phases, the ﬁrst being the 20 nm particle
treatments followed by the 100 nm particle treatments.
Rats were weighed prior to and weekly during the experiment. Individual body
weights (BW) of the rats were used to calculate the individual dose levels.
2.4. Histopathology
At 24 h after the last injection, rats were anaesthetized with isoﬂurane (Isoﬂu,
AST Pharma, Oudewater, The Netherlands) in oxygen and subsequently euthanized
by drawing blood from the abdominal aorta. After collecting blood, rats were
evaluated macroscopically for gross lesions. The following organs were examined
and sampled: adrenals, brain, bone marrow, small intestines (duodenum, jejunum,
ileum), large intestines (caecum, colon, rectum), heart, kidney, liver, lung, lymph
nodes (mesenteric and popliteal), esophagus, pituitary, spleen, stomach, testis (or
ovaria), and thymus. Organ weights were determined except for bone marrow, pi-
tuitary and gastrointestinal tract.
All tissue sampleswere ﬁxed in 4% neutral buffered formaldehyde (10% formalin)
and routinely processed (Hematoxylin and Eosin staining) for histopathology.
Routine histopathology was performed for the following treatments: 20 nm Ag-
NP 6 mg/kg b.w. (3 male and 3 female animals) and 2 mg/kg b.w. (3 male and 3
female animals), 100 nm Ag-NP 6 mg/kg b.w. (4 male and 4 female animals), and
phosphate buffer control treated animals (6 male and 6 female animals).
2.5. Hematology
Hematology and clinical chemistry was performed on blood samples obtained at
autopsy. Blood was collected in EDTA-coated tubes. Hematological parameters
included white blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (Hb),
hematocrit (Ht), mean corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distri-
bution width (RDW), hemoglobin distribution width (HDW), platelet (PLT) count,
and mean platelet volume (MPV). All hematology parameters in the blood samples
were determined in an Advia 120 Hematology Analyzer (Siemens, Germany). In
addition, blood smears were prepared for visual evaluation.
2.6. Clinical chemistry
After collection of blood serum and storage at 20 C the following parame-
ters were determined: albumin (ALB), alkaline phosphatase (ALP), alanine
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Fig. 1. A) Body weight of male rats presented as a percentage of the weight at the start of the experiment at day 0 (¼100%). Animals were treated intravenously for 28 days with
different doses of 20 nm Ag-NP. B) Body weight of female rats presented as a percentage of the weight at the start of the experiment at day 0 (¼100%). Animals were treated
intravenously for 28 days with different doses of 20 nm Ag-NP. C) Dose response analysis (Hill equation) of body weight as a function of intravenous administration for 28 days of
20 nm Ag-NP. Body weight was determined on day 29 and expressed as weight increase versus day 0. The conﬁdence interval for the CED05 of 3.9 mg/kg body weight was (2.8, 6.1)
mg/kg body weight. B females, D males.
W.H. De Jong et al. / Biomaterials 34 (2013) 8333e8343 8335aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl
transpeptidase (GGT), amylase (AMY), creatinin kinase (CK), lactate dehydroge-
nase (LDH), sodium (Na), potassium (K), glucose (GLU), urea, creatinin (CRE),
cholesterol (CHOL) and total protein (TP).
2.7. Bone marrow
Cells were collected by ﬂushing 4 ml Impuls Cytometer Fluid through the femur.
The concentration of nucleated cells was determined in a Coulter Counter.
2.8. Determination of immune parameters
2.8.1. Spleen cell distribution
The spleenwas weighed and aweighed part of the spleenwas collected in tissue
culture medium of which spleen cells were isolated. Relative spleen cell distribution
was determined by ﬂuorescence-activated cell sorter (FACS) analysis as described by
Tonk et al. [22]. Spleen single-cell suspensions were prepared and evaluated for
subset distribution by 3-color ﬂow cytometry. The following monoclonal antibodies
were used: allophycocyanin (APC)-conjugated mouse anti-rat CD3 (clone 1F4, T
lymphocytes), R-phycoerythrin (PE)-conjugatedmouse anti-rat CD8a (clone OX-8, T-
suppressor/cytotoxic cells), ﬂuorescein isothiocyanate (FITC)-conjugated mouse
anti-rat CD4 (clone OX-35, T helper cells), FITC-conjugated mouse anti-rat CD45RA
(clone OX-33, B lymphocytes), and PE-conjugated mouse anti-rat CD161a (clone 10/
78, NK cells); all from Pharmingen, San Diego, CA, USA. Single-cell suspensions were
incubated with the conjugated mAbs for 30 min at 4 C in the dark. The cells were
washed twice with wash buffer (5% BSA in PBS), resuspended in 0.1% para-
formaldehyde in PBS, and analyzed on a FACSCalibur ﬂow cytometer (BDBiosciences, San Diego, CA, USA). A total of 10, 000 events were recorded per sample
and analyzed.
2.8.2. Natural killer (NK) cell activity
Spontaneous cytotoxicity of spleen cell populations was evaluated in an in vitro
51Cr-release assay for determination of NK cell activity as described previously
[22,23]. Spleen single-cell suspensions were adjusted in a standard medium con-
taining 10% FBS. The YAC target cells (1106 cells/100 ml) were labeled with 3.7MBq
Na251CrO4 (Amersham, Buckinghamshire, UK) for 45 min at 37 C, washed 5, and
resuspended in standard medium containing 10% FBS at 1 105 viable cells/ml. The
NK cell activity assays were performed in 96-well polystyrene U-bottommicroplates
(Costar, Cambridge, MA, USA) for each sample in triplicate. Aliquots of 1 104 target
cells were added to each well containing the appropriate number of effector cells to
give effector cell (E) to target cell (T) ratios (E:T) of 200:1, 100:1, 50:1, and 25:1, to a
ﬁnal volume of 200 ml. Controls included a spontaneous 51Cr-release control (target
cells þ medium) and a maximum 51Cr-release control (target cells þ 1% triton).
Plates were centrifuged for 5 min at 1200 rpm and incubated at 5% CO2, 37 C for 4 h.
Radioactivity in the cell supernatants was measured using a gamma counter
(Packard, Tilburg, The Netherlands) as counts per minute (cpm). Percentage of
cytotoxicity was calculated as:
%Cytotoxicity ¼ðsample cpm spontaneous cpm
=maximum cpm spontaneous cpmÞ  100
2.8.3. Mitogen stimulated lymphocyte proliferation
Lymphocyte proliferation responses of spleen cells to mitogens (lipopolysac-
charide, LPS and concanavalin A, ConA) were evaluated with the [3H]-thymidine
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Fig. 1. (continued)
Table 3
Critical Effect Doses of toxicological endpoints after 28 days IV administration of
20 nm silver nanoparticles.
End point BMD,
mg/kg b.w.
Conﬁdence interval,
(5th%e95th%)
mg/kg b.w.
Maximal response
(% of control)
Body weight (day 28) 5.26 2.89e23.69 5.7
Body weight (d28/d0) 3.89 2.80e6.13 7.6
Spleen weight 0.37 0.12e1.04 þ132
Relative spleen weight 0.25 0.14e0.64 þ150
Thymus weight 0.01 0.001e0.14 17.4
Relative thymus weight 0.02 0.002e0.14 15.2
Liver weight 2.20 1.39e4.87 þ14.5
Relative liver weight 1.57 1.18e2.21 þ21.3
The bench mark dose (BMD) at 5% change compared to controls was calculated as a
geometric mean of the exponential and Hill models used in the regression analysis.
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in triplicate in a U-bottom 96-well plate and stimulated with 15 mg/ml LPS
(SigmaeAldrich, Zwijndrecht, The Netherlands) or 5 mg/ml Concanavalin A (ConA;
ICN Biochemicals, Aurora, OH, USA) for 48 and 72 h, respectively. 3H-thymidine
(Amersham, Buckinghamshire, UK) was added for the last 20e22 h of incubation.
The cells were harvested on glass ﬁber ﬁlters (LKB-Wallac, Turku, Finland) using a
multiple cell culture harvester (LKB-Wallac). The 3H-thymidine activity was
determined using a liquid scintillation counter (1205 Betaplate TM; LKB-Wallac,
Turku, Finland). For further calculations, the median of the triplicates was used.
2.8.4. Cytokine production of spleen cells
Supernatants of mitogen stimulated cells (see above) were harvested for LPS
stimulated cells at 24 h incubation (37 C, 5% CO2), and for Concanavalin A stimu-
lated cells at 48 h incubation. Interleukin (IL)-1b, IL-2, IL-4, IL-6, IL-10, IL-17, IL-13,
interferon (IFN)-g, TNF-a and granulocyteemacrophage colony-stimulating factor
(GM-CSF) were measured in the collected supernatants using a MILLIPLEX Map Kit
(Millipore, Billerica, MA, USA).
2.9. Immunoglobulins
After collection of blood serum and storage at 20 C immunoglobulin levels
were determined in an enzyme linked immunosorbant assay (ELISA) using mouse
monoclonal antibodies against rat IgG, IgM and IgE, respectively.
2.10. Statistical analysis
Data are presented as means with their standard deviation. Treatment effects of
20 nm particles were evaluated using the bench mark dose (BMD) approach, by
ﬁtting a nonlinear regression model to the data of all individual animals. The choice
of the model for evaluating the BMD (also called CED, (critical effect dose), for
continuous endpoints) follows from a procedure of applying likelihood ratio tests on
the members of the following nested family of models.
Model 1: y ¼ a
Model 2: y ¼ a exp(bx)
Model 3: y ¼ a exp(bxd)
Model 4: y ¼ a(c  (c  1)exp(bx))
Model 5: y ¼ a(c  (c  1)exp(bxd)),
where y is the response, and x denotes the applied concentration. The parameter a
represents the level of response at concentration zero, and b can be considered as
the parameter reﬂecting the potency of the agent. At high doses, models 4 and 5
level off to the value ac, so the parameter c can be interpreted as the maximum
relative change compared to the background. Parameter d can be interpreted as the
‘steepness’ of the curve (i.e., rate of change in response for a percent change in dose).
All these models are nested to each other, except models 3 and 4, which both have3 parameters. Therefore, these two models cannot be (formally) compared to each
other by a likelihood-ratio test.
For each data set (end point measured), one of these models was selected by
applying the likelihood ratio test to establish whether extension of the model by
increasing the number of parameters resulted in a statistically improvement of the
ﬁt to the doseeresponse data. The selected model was used to estimate the BMD
(CED) and the associated 90%-conﬁdence interval (see results). For these endpoints
a critical effect size (CES) or bench mark response (BMR) was chosen The conﬁ-
dence interval was determined using a (parametric) boot strap method [24], as
follows. Once a model is selected for describing the doseeresponse data, this ﬁtted
model is used as a basis for generating 200 artiﬁcial data sets (according to the
Experimental design) by Monte Carlo sampling. For each generated data set, the
CED is re-estimated. Taking all these CEDs together results in a distribution rep-
resenting the uncertainty associated with the CED estimate. The 5th and 95th
percentiles of this empirical distribution were determined, serving as a two sided
90% conﬁdence interval (c.i.) of the estimated CED [25]. The results of the
BMD experimental design were analyzed using PROAST software version 32.2
(http://www.rivm.nl/en/Library/Scientiﬁc/Models/PROAST), RIVM, Bilthoven, The
Netherlands)). The critical effect size (CES) or benchmark response (BMR) for
general and speciﬁc toxicity endpoints was chosen at 5% deviation of the control
values, In this study consensus default BMR values were used as proposed by the
European Food Safety Authority [21], 5% for continuous data and 10% (extra risk) for
quantal data. Based on the regression model a maximal response as a percentage of
control animals was calculated.
Statistical analysis of the effects of the administration of 100 nm Ag-NP was
performed with SPSS software (SPSS Inc., Chicago, IL, USA).
Fig. 2. Body weight of male and female rats during 28 days of intravenous treatment with 100 nm Ag-NP presented as a percentage of the weight at day 0 (¼100%).
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3.1. Animal observation and effect on body weights
The treatment efﬁcacy was well above 90% of the intended
doses. The total dose administered for the various treatment groups
varied between 93% and 99% of the intended dose (data not shown).
No clinical signs for toxicity were observed during the 28-days
exposure period for treatment with either 20 nm Ag-NP or
100 nm Ag-NP. Both male and female rats in the highest dose group
(6 mg/kg body weight) of the 20 nm Ag-NP showed lower body-2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5
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Fig. 3. Dose response analysis (Hill equation) of spleen weight as a function of intra-
venous administration for 28 days of 20 nm Ag-NP. Spleen weight was determined on
day 29. The conﬁdence interval of the CED05 of 0.39 mg/kg body weight was (0.12,
1.04) mg/kg body weight.B females, D males.weights after 4 weeks of intravenous administration of the 20 nm
nanosilver (Fig. 1). The BMD analysis showed that males and fe-
males did not differ statistically signiﬁcantly in the doseeresponse
for body weight (apart from background weight). The CED05 (dose
at 5% deviation from control) for a decrease in BW was 5.26 mg/kg
b.w. and resulted in a conﬁdence interval of (2.9, 24) mg/kg b.w.,
but when evaluating the body weight gain as a percentage of the
weight at day 0 it reduced to a CED05 of 3.89 mg/kg b.w. with a
conﬁdence interval of (2.8, 6.1) mg/kg b.w. (Fig. 1, Table 3). The
maximal response calculated from the regression models indicates
a minor weight difference of 6e8% compared to control animals.-2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5
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Fig. 4. Dose response analysis (Hill equation) of liver weight as a function of IV
administration for 28 days of 20 nm Ag-NP. Liver weight was determined on day 29.
The conﬁdence interval for the CED05 of 2.20 mg/kg body weight was (1.39, 4.88) mg/
kg body weight. B females, D males.
Fig. 5. Presence of brownish pigment in red pulp of the spleen after 28 days intra-
venous administration of 20 nm Ag-NP. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Presence of brown pigment in Kupffer cells of the liver after 28 days intrave-
nous administration of 20 nm Ag-NP. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 7. Presence of pigment in sinusoids of lymph node after 28 days intravenous
administration of 20 nm Ag-NP. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 8. Presence of pigment (nanoparticles) in granuloma of the lung after 28 days
intravenous administration of 100 nm Ag-NP. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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animals was observed as well (Fig. 2).3.2. Macroscopic evaluation and effect on organ weights
Macroscopic examination of the rats revealed enlarged
brownish colored spleens and livers, and enlarged and dark colored
lymph nodes in the highest dose groups.
Heart, kidneys, adrenals, brain, testes and epididymis were
weighed and showed no differences in the different dose groupsTable 4
BMD analysis of clinical chemistry and hematology parameters.
Clinical chemistry
Blood
BMD,
mg/kg b.w.
Conﬁdence interval,
(5th%e95th%) mg/kg b.w.
Maximal response,
(% of control)
ALB 2.60 1.66e5.28 11
ALP 0.99 0.41e1.22 þ81
ALT 0.62 0.43e0.91 þ69
AMY 1.36 0.93e2.24 þ25
AST 0.73 0.47e1.22 þ56
GLU 1.24 0.64e4.38 21
LDH 0.60 0.29e1.80 37
TP 3.97 2.76e7.06 þ7.7
UREA 3.04 1.66e15.2 þ10
CK 0.66 0.31e4.02 32
Hematology BMD,
mg/kg b.w.
Conﬁdence interval,
(5th%e95th%)
mg/kg b.w.
Maximal response,
(% of control)
Bone marrow
WBC (109/l)
0.98 0.47e3.94 26
RBC (1012/l) NS
Hb (mmol/l) 2.75 0.97e4.94 9.1
Ht (l/l) 4.22 2.75e8.42 7.0
MCV (ﬂ) 3.54 2.82e4.62 8.3
MCH (fmol) 2.75 2.26e3.44 10.4
MCHC (mmol/l) 13.40 8.45e31.92 2.3
RDW (%) 5.03 3.29e10.6 þ6.0
HDW (mmol/l) 1.37 0.73e1.59 76
PLT (109/l) NS
MPV (ﬂ) 1.84 1.29e2.98 17.8
Reticulocytes (109/l) 0.88 0.58e1.48 þ43
Reticulocytes (%) 0.90 0.58e1.63 þ41
Blood WBC (109/l) NS
For abbreviations see Materials and methods. The bench mark dose (BMD) at 5%
change compared to controls was calculated as a geometric mean of the exponential
and Hill models used in the regression analysis.
Fig. 9. Blood neutrophilic granulocytes after 28 days IV treatment with 20 nm Ag-NP. Signiﬁcant increase in response p < 0.05 (ANOVA on all groups).
W.H. De Jong et al. / Biomaterials 34 (2013) 8333e8343 8339(Ag-NP 20 nm) compared to the control, whereas for liver a weight
increase and for the thymus a weight decrease was observed
(Table 3). Both for the absolute and relative spleen weight an in-
crease was observed with a CED05 of 0.37 mg/kg b.w. (conﬁdence
interval 0.12, 1.04) and 0.25 mg/kg b.w. (conﬁdence interval 0.14,
0.64), respectively (Table 3). The dose response analysis of the
spleenweight increase is presented in Fig. 3. After treatment for 28
days with 100 nm Ag-NP (6 mg/kg b.w.) in both male and female
animals spleenweight was similarly increased compared to control
(phosphate treated) animals (Supplementary data Table S1). BMDTable 5
BMD analysis of immune parameters.
Immune parameters antibodies in blood BMD, mg/kg b.w. Conﬁden
IgM 0.15 0.02e0.7
IgG NS
IgE 0.02 0.00e0.2
Immune parameters in spleen cells BMD, mg/kg b.w. Conﬁdenc
Spleen cellularity (107) 0.28 0.01e0.52
NK: % release/culture (100:1) 0.06 0.04e0.11
NK activity/spleen (100:1) 0.12 0.04e0.29
CD8 T-cytotoxic-cell/107 spleen cells 0.43 0.29e0.63
CD4 T-helper-cell/107 spleen cells 0.40 0.27e0.59
CD3 T-cell/107 spleen cells 0.42 0.30e0.60
CD161a NK-cell/107 spleen cells 0.71 0.45e1.26
CD45RA B-cell/107 spleen cells 0.14 0.06e0.34
CD4/CD8 NS
T-cells:B-cells 1.83 0.99e9.78
CD8 T-cytotoxic-cell/spleen 0.18 0.16e0.42
CD4 T-helper-cell/spleen 0.17 0.15e0.41
CD3 T-cell/spleen 0.12 0.04e0.23
CD161a NK-cell/spleen 0.25 0.20e0.51
CD45RA B-cell/spleen 0.12 0.04e0.27
ConA stimulation cpm/culture 0.26 0.02e1.26
ConA stimulation cpm/spleen 0.07 0.03e0.17
LPS stimulation cpm/culture 0.04 0.0001e0
LPS stimulation cpm/spleen 0.74 0.44e1.56
LPS spleen cells IL-1b 0.54 0.14e1.19
LPS spleen cells IL-6 0.56 0.30e1.19
LPS spleen cells IL-10 1.08 0.51e5.29
LPS spleen cells TNF-a 0.28 0.21e0.66
Con A spleen cells IL-10 0.81 0.38e3.18
Con A spleen cells IFN-g 0.59 0.32e1.26
The bench mark dose (BMD) at 5% change compared to controls was calculated as a geoanalysis showed for the liver an increase in weight for males and
females after treatment with 20 nm Ag-NP (Fig. 4), CED05 2.20 mg/
kg b.w. (c.i. 1.39, 4.88), and for female animals exposed to 100 nm
Ag-NP (Supplementary data Table S1B).
3.3. Histopathology
In the histopathological evaluation pigment was observed in
various organs including spleen, liver, and lymph nodes (Figs. 5e7).
The pigment itself was not further identiﬁed but could be ascribedce interval, (5th%e95th%) mg/kg b.w. Maximal response, (% of control)
7 þ372
5 þ3430
e interval, (5th%e95th%) mg/kg b.w. Maximal response, (% of control)
þ104
85
67
þ124
þ141
þ127
þ58
þ103
þ18
þ341
þ377
þ374
þ216
þ314
þ43
þ185
.29 24
þ55
þ94
39
24
50
30
37
metric mean of the exponential and Hill models used in the regression analysis.
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ulations after 28 days intravenous treatment with 100 nm Ag-NP.
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administration of 20 nm Ag-NP the pigment in the spleen was
mainly observed in the red pulp, while after 100 nm Ag-NP the
pigment was observed in both the red and white pulp of the spleen.
The pigment was also observed in the sinusoids of the lymph nodes
evaluated (mesenteric and popliteal lymph node). In the liver the
pigment (nanoparticles) was present in the Kupffer cells lining the
walls of the venous sinusoids. The pigment was also observed in
venous endothelial cells and in small foci of inﬂammatory cells.
These foci are also present (without pigment) in control animals
and are generally considered background histopathology in the rat
strain used. Incidentally pigment was also observed in the kidney,
adrenal glands and in most of the intestinal tract (jejunum, ileum,
caecum, colon and rectum).
In the lung small granulomas were observed partly caused by
the injection technique as indicated by the presence of hair frag-
ments. Some granulomas contained black pigment after injection of
100 nm Ag-NP (Fig. 8).
3.4. Hematology and clinical chemistry
In general minor alterations were observed in clinical chemistry
parameters (Supplementary data Table S2). Several clinical chem-
istry parameters showed a dose related effect including albumin
(ALB), alkaline phosphatase (ALP), alanine transaminase (ALT),
amylase AMY, aspartate transaminase (AST), creatinin kinase (CK),
glucose (GLU), lactate dehydrogenase (LDH), total protein (TP), and
urea (Table 4). The increased ALP, ALT and AST are indicative for
liver damage. For blood several parameters associated with red
blood cell generation showed a signiﬁcant decrease in the highest
doses administered which could be conﬁrmed by dose response
analysis with a CES of 5% (Table 4). The hematocrit (Ht), mean
corpuscular cell volume (MCV), mean corpuscular cell hemoglobin
(MCH), and hemoglobin (Hb) level in red blood cells showed a
limited decrease after treatment with the 20 nm Ag-NP. The
number of reticulocytes was increased indicating red blood cell
productionwhich might be associated with the decreases observed
for the hemoglobin parameters. After treatment with 100 nm Ag-
NP a similar decrease was observed that was, however, not signif-
icant for all four parameters (data not shown). Although the total
number of WBC was not increased, the absolute number of blood
neutrophilic granulocytes showed a signiﬁcant dose related in-
crease with the 20 nm Ag-NP (p < 0.05 ANOVA, Fig. 9). For the
treatment with 100 nm Ag-NP similar effects on the blood pa-
rameters were observed (data not shown). For bone marrow no
differences in cell count were observed after treatment with 20 nm
or 100 nm Ag-NP (data not shown).
3.5. Immunotoxicity
An increase in IgM and IgE serum levelswas seen after treatment
with both 20 nm and 100 nm Ag-NP (Table 5, Supplementary data
Table S3). In the spleen T cell, B cell and NK cell populations showed
an increase after treatment with 20 nm Ag-NP (Table 5). Similarly,
for 100 nm Ag-NP an increase in T, B and NK cell populations was
observed (Fig. 10). This increase in cell numbers can be considered
responsible for the weight increase of the spleen. Mitogen re-
sponses to B (LPS) and T (Concanavalin A) cell mitogens showed
increased responses per spleen due to the increased cell number
(Table 5) Interferon-g, TNF-a, IL-6 and IL-10 cytokine production
were decreased after treatment with 20 nm Ag-NP, whereas IL-1b
production was increased (Table 5). For the 100 nm Ag-NP treat-
ment only the IL-10 production was decreased (data not shown).
Both nanoparticles (20 nm and 100 nm Ag-NP) induced an
almost complete suppression of theNK cell activity at all effector-to-target ratios (200:1, 100:1, 50:1, 25:1) investigated (Table 5, Fig. 11).
The suppression of NK cell activity by the 20 nm Ag-NP started at a
dose of 0.22mg/kg b.w., but wasmost pronounced at doses of 2mg/
kg and 6 mg/kg body weight. The CED05 for the suppression of NK
cell activity was 0.06 mg/kg b.w. with a conﬁdence interval (0.04,
0.11) when evaluated per NK cell culture, and 0.12mg/kg b.w. with a
conﬁdence interval of (0.04, 0.29) when evaluated per spleen.
4. Discussion
The ﬁrst indication for a toxic effect of the intravenously
administered 20 nm and 100 nm Ag-NP was the observed decrease
in body weight gain, conﬁdence interval CED05 (2.8, 6.1). The
weight gain in the 6 mg/kg body weight treated animals was
approximately 66% of the weight gain in the control animals (33%
weight increase in the controls versus 19%e24% weight increase in
the Ag-NP treated groups). The increase in spleen weight with a
CED05 around 0.3 mg/kg b.w., and the decrease in thymus weight
CED05 around 0.01 mg/kg b.w. were the most sensitive general
toxicity parameters for Ag-NP toxicity. The increase in spleenweight
was 2e3 fold. Also for the liver a signiﬁcant weight increase was
observed (Fig. 4). Brownish colored pigment was observed in
various organs like spleen, liver and lymph nodes, while gross
pathological lesions were not observed, the one exception being the
enlarged spleen in all animals treated at the highest administered
doses of both 20 nm and 100 nmAg-NP. For the 20 nmAg-NP a clear
dose response could be observed (Fig. 3). It was remarkable that the
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Fig. 11. NK cell activity in the spleen of rats after 28 days intravenous treatment with 20 nm or 100 nm Ag-NP.
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with any inﬂammatory reaction. Also in lymph nodes the presence
of Ag-NP was not accompanied by an inﬂammatory response.
However, the increase of neutrophilic granulocytes in the blood
does indicate an inﬂammatory response of the body (Fig. 9). Yet in
the various other organs investigated no indications for an inﬂam-
mation could be observed. Only in the lung isolated areas with a
granulomatous inﬂammation could be identiﬁed. These granulo-
matous inﬂammatory reactions were partly caused by the injection
technique as indicated by the presence of foreign body material in
the inﬂammation, and partly by the Ag-NP as indicated by the
presence of granular pigment in the inﬂammation (Fig. 8). Such
granulomatous inﬂammation is a common side effect of prolonged
repeated intravenous administrations as with every injection there
is a chance of injecting some skin and/or hair material in the cir-
culation. An overviewof the results obtained in the 28days repeated
dose toxicity study with 20 nm and 100 nm Ag-NP is presented in
Table 6.
In previous studies, a 28 days and 90 days inhalation study with
heat generated aerosols of silver nanoparticles (size 12e15 nm (28
days study), and 19 nm (90 days study), and exposure for 6 h/dayﬁve days per week, no effects on body weight were observed
[16,17]. Also in a 28 days oral toxicity study in rats conducted by the
same research group no effect on body and minimal effects on or-
gan weight (increase in brain weight in the high dose group, and in
liver weight in the mid dose group) was observed at orally
administered doses up to 1000mg/kg bodyweight per day [19]. In a
more recent study Van Der Zande et al. [20] also did not ﬁnd an
effect on body and organ weight in a 28 days oral toxicity study of
nanosilver in rats. Also in mice the oral administration of 1 mg/kg
body weight of 22 nm, 42 nm, 71 nm, and 323 nm Ag nanoparticles
for 14 days did not result in an effect on body weight [26]. In our
study we used the intravenous route bypassing the need for
crossing cellular barriers in the lung and GI-tract to evaluate
possible systemic toxic effects of Ag-NP for 20 nm and 100 nm Ag-
NP. So, the whole dose administered was systemically available and
the internal exposure (as presented by the intravenous dose)
resulting in toxic responses could be identiﬁed using the bench-
mark approach. In the present study a reduction in body weight
was observed at the highest dose of 6 mg/kg body weight, a dose
that was most likely not obtained in the inhalation and oral toxicity
studies. The BMD analysis indicated that the dose for a 5% reduction
Table 6
Overview of important toxic effects of silver nanoparticles after 28 days intravenous administration of 20 nm or 100 nm Ag-NP in rats.
20 nm Ag-NP 100 nm Ag-NP
Effect Sex CED05 mg/kg b.w. Result Effect Sex Dose mg/kg b.w. Result
General
Body weight gain M/F 3.89e5.26 Y Body weight gain M/F 6 Y
Liver weight M/F 1.57e2.20 [ F 6 [
Spleen
Spleen weight M/F 0.25e0.37 [[[ Spleen weight M/F 6 [[[
Spleen cell number M/F 0.28 [[ Spleen cell number M/F [[
T cells spleen M/F 0.12 [[ T cells spleen M/F [[
B cells spleen M/F 0.12 [[ B cells spleen M/F [[
NK cells spleen M/F 0.25 [ NK cells spleen M/F [
NK cell activity M/F 0.06e0.12 YYY NK cell activity M/F YYY
IL-10 production M/F 0.28e0.58 Y IL-10 production M/F Y
IFN-g production M/F 0.59 Y IFN-g production M/F e
Thymus
Thymus weight M/F 0.01e0.02 Y Thymus weight M/F e
W.H. De Jong et al. / Biomaterials 34 (2013) 8333e83438342in body weight was somewhere between 3 and 6 mg/kg b.w.
(Table 3). In both the 28 days and 90 days inhalation study no effect
was seen on spleen weight in contrast to the present intravenous
study [16,17]. Also in the rat oral studies no effect on spleen weight
was observed [19,20]. In the mouse oral study spleen weight was
not reported [26]. Our BMD analysis showed that 20 nm Ag-NP
induced a 5% increase in spleen weight already at around 0.3 mg/
kg body weight. In both the 28 days and 90 days inhalation study
someminimal histopathologywas noted in the liver, whereas in the
90 days inhalation study also minimal inﬂammatory responses
were noted in the lung that were not seen in the 28 days inhalation
study [16,17]. Our results on clinical chemistry and hematology
differ from the inhalation studies as in both inhalation studies no
consistent alterations were seen in the clinical chemistry of the
blood and cellular blood parameters, whereas we observed a dose
related effect for several clinical chemistry parameters. These dif-
ferences may be due to the actual internal dose being higher in our
studies to which organs like liver, spleen and bone marrow were
exposed. In the blood an effect was noted on some red blood cell
parameters (hematocrit, mean corpuscular cell volume, mean
corpuscular hemoglobin, and blood hemoglobin). The alterations in
the red blood cells may indicate an effect of the nanoparticles on
hemoglobin syntheses during red blood cell maturation/formation
in the bone marrow. The increase in reticulocytes in the blood in-
dicates an increased possibly compensatory production of red
blood cells. A 28 days oral toxicity study in mice found liver toxicity
as indicated by an increase in liver enzyme levels of alkaline
phosphatase (ALP), alanine transaminase (ALT), and aspartate
transaminase (AST) in serum [26]. Similarly, we found an increase
in these liver enzyme levels in serum of 20 nm Ag-NP treated rats.
However, although the presence of Ag-NP could be observed in the
liver Kupffer cells, alterations indicating liver histopathology were
not observed.
In addition to common toxicological endpoints like body and
organ weight, blood clinical chemistry and hematology, and his-
topathology, immune toxicity was evaluated as in our previous
study to the tissue distribution of Ag-NP the spleen was one of the
main target organs [13]. Previously in a 28 days oral toxicity study
of nanosilver no effects on the immune systemwere observed [20].
In our study an increase in IgM and IgE antibody levels in serum
was observed. Also in the mouse oral study [26] an increase in IgE
antibodies in blood serumwas found but cellular blood parameters
like NK, B and T cell populations were not altered. The increase in
IgM and IgE immunoglobulin levels might be explained by the
increased number of B cells in the spleen. As antibodies play a
prominent role in the defense against various infectious agents it
needs to be determined what effects the treatment of Ag-NP wouldhave in a microbial infection or antigen challenge model. Several
models, e.g. immunization with keyhole limpet hemocyanin (KLH),
bacterial or viral infectious agents are available to study the effect of
xenobiotics on both the cellular and humoral immunity [27].
In the spleen indications were found for effects of Ag-NP treat-
ment on T cell activity, as indicated by a decrease in the production
of IFNg and IL-10 after Concanavalin A stimulation of the spleen
cells. B cell activity was also affected as indicated by a decrease in IL-
6, IL-10 and TNF-a production, and increase in IL-1b production
after LPS stimulation of the spleen cells. In the mouse 28 days oral
study an increase in IL-10 in serumwas noted [26]. In our study the
most pronounced toxic effect of the treatment with Ag-NP was
noted for the activity for natural killer (NK) cells in the spleen. The
NK cell activity was almost completely suppressed after treatment
of high doses with both 20 nm and 100 nm Ag-NP. Spleen NK cell
activity was found to be the most sensitive parameter of the func-
tional immune parameters investigated. The demonstration of the
severe NK cell suppression needs to be further investigated in im-
mune challenge models to evaluate the functional impact of such
severe suppression in terms of resistance against outside challenges.
For the toxicity of Ag-NP there is still the question whether
the toxicity is due to the nanoparticles themselves or due to the
release of ions from the nanoparticles. Recently it was shown
that the ion content of an Ag-NP preparation inﬂuences the
toxicity of the nanoparticle preparation with preparations of a
higher ion content being more toxic for cells in vitro [28]. The
total toxicity could be ascribed to both the ion content and the
nanoparticles in the preparation as in this in vitro study also
cytotoxicity of the silver nanoparticles themselves was demon-
strated. In vivo after oral administration the silver concentration
in organs was highly correlated with the Agþ ion of the nano-
silver suspension [20].
5. Conclusions
The most pronounced effects of the intravenous administration
of both 20 nm and 100 nm Ag-NP were the increase in spleen
weight and the almost complete suppression of the natural killer
(NK) cell activity in the spleen at the higher doses. As the NK cell is
part of the innate immune system such suppression may have an
effect on the resistance against threats from outside such as viral
infections or from newly developed cancerous cells for which NK-
cells are a ﬁrst line of defense. The present study shows that Ag-
NPs induce general toxicity in the rat at an internal exposure at a
CED05 of approximately 0.3 mg/kg body weight (spleen enlarge-
ment) whereas immune toxicity (reduced thymus weight) is
already induced at a CED05 dose of 0.01 mg/kg body weight. In
W.H. De Jong et al. / Biomaterials 34 (2013) 8333e8343 8343addition, several functional immune parameters were affected like
NK cell activity with a CED05 of 0.06 mg/kg body weight, and LPS
mitogen stimulation of spleen cells (CED05 0.04 mg/kg), and
cytokine production by stimulated spleen cells (CED05 0.3e1.0 mg/
kg body weight). This information can be used for evaluation of
maximal exposure by other routes, e.g. inhalation and oral,
providing the availability of appropriate kinetic models to estimate
internal systemic exposure.
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